{
    "clinical_study": {
        "@rank": "148144", 
        "arm_group": {
            "arm_group_label": "Macitentan", 
            "arm_group_type": "Experimental", 
            "description": "10 mg once daily"
        }, 
        "brief_summary": {
            "textblock": "Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in\n      patients with PAH.\n\n      To assess the long-term safety of macitentan in patients with pulmonary arterial\n      hypertension (PAH) beyond treatment in the AC-055-310 study."
        }, 
        "brief_title": "Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Arterial Hypertension", 
            "PAH"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the long-term safety of macitentan in patients with pulmonary arterial\n      hypertension (PAH) beyond treatment in the AC-055-310 study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent prior to any study-mandated procedure.\n\n          2. Patients with PAH who completed the ORCHESTRA study (AC-055-310) as scheduled\n\n          3. Women of childbearing potential (as defined below) must:\n\n               -  Have a negative serum pregnancy test at Visit 1 (i.e., Visit 4 of study AC 055\n                  310) and agree to perform monthly serum pregnancy tests.\n\n               -  Agree to use two reliable methods of contraception in parallel, from Visit 1\n                  until 1 month after study drug discontinuation (see details below).\n\n                    -  A female is considered to have childbearing potential unless she meets at\n                       least one of the following criteria:\n\n                         -  Previous bilateral salpingo and/or oophorectomy, or hysterectomy.\n\n                         -  Premature ovarian failure confirmed by a specialist.\n\n                         -  Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis.\n\n                         -  Postmenopausal, defined as 12 consecutive months with no menses\n                            without an alternative medical cause.\n\n                    -  Of the two contraceptive methods that must be used, one must be from Group\n                       1, and one must be from Group 2, defined as follows:\n\n                         -  Group 1: Oral, implantable, transdermal or injectable hormonal\n                            contraceptives, intrauterine devices, female sterilization (tubal\n                            ligation or non-surgical sterilization, e.g., permanent contraception\n                            with Essure procedure), or partner's sterilization (vasectomy). If a\n                            hormonal contraceptive is chosen from this group, it must be taken for\n                            at least one month prior to enrollment. Alternatively, if the Essure\n                            procedure is chosen as a contraceptive method, a hysterosalpingogram\n                            must have been performed to confirm correct location of the\n                            microinserts and tubal occlusion (as per manufacturer's\n                            recommendations).\n\n                         -  Group 2: Female or male condoms, diaphragm or cervical cap, any of\n                            them in combination with a spermicide.\n\n                    -  Sexual abstinence, rhythm methods, or contraception by the partner alone\n                       are not considered as acceptable methods of contraception for this study.\n\n        Exclusion Criteria:\n\n          1. Patients who prematurely discontinued study drug in study AC-055-310.\n\n          2. Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to\n             become pregnant during the study.\n\n          3. AST and/or ALT more than 3 X ULN."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112487", 
            "org_study_id": "AC-055-311"
        }, 
        "intervention": {
            "arm_group_label": "Macitentan", 
            "description": "10 mg once daily", 
            "intervention_name": "Macitentan", 
            "intervention_type": "Drug", 
            "other_name": "ACT-064992"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pulmonary arterial hypertension", 
            "PAH"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "laurent.savale@gmail.com", 
                "last_name": "Laurent Savale", 
                "phone": "33145217991"
            }, 
            "facility": {
                "address": {
                    "city": "Le Kremlin-Bic\u00eatre", 
                    "country": "France", 
                    "zip": "94270"
                }, 
                "name": "CHU de Bic\u00eatre"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Extension of AC-055-310, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT\u2122", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "France: Conseil National de l'Ordre des M\u00e9decins", 
                "Italy: Ethics Committee", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment-emergent adverse events (AEs)\nAEs leading to premature discontinuation of study drug\nTreatment-emergent serious adverse events (SAEs)\nProportion of patients with treatment-emergent ALT and/or AST abnormality (> 3, > 5, and > 8 x ULN) associated or not with total bilirubin > 2 x ULN.\nProportion of patients with treatment-emergent hemoglobin abnormality (\u2266 100 g/L, and \u2266 80 g/L)", 
            "measure": "To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment in the AC-055-310 study.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to end of treatment visit (around 6 months on average)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Actelion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}